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Cathepsin S (CTSS) has previously been implicated in a number of cancer types, where it is associated with poor clinical features
and outcome. To date, patient outcome in breast cancer has not been examined with respect to this protease. Here, we carried
out immunohistochemical (IHC) staining of CTSS using a breast cancer tissue microarray in patients who received adjuvant
therapy. We scored CTSS expression in the epithelial and stromal compartments and evaluated the association of CTSS expression
with matched clinical outcome data. We observed differences in outcome based on CTSS expression, with stromal-derived CTSS
expression correlating with a poor outcome and epithelial CTSS expression associated with an improved outcome. Further subtype
characterisation revealed high epithelial CTSS expression in TNBC patients with improved outcome, which remained consistent
across two independent TMAcohorts. Further in silico gene expression analysis, using both in-house and publicly available datasets,
confirmed these observations and suggested high CTSS expression may also be beneficial to outcome in ER-/HER2+ cancer.
Furthermore, high CTSS expression was associated with the BL1 Lehmann subgroup, which is characterised by defects in DNA
damage repair pathways and correlates with improved outcome. Finally, analysis of matching IHC analysis reveals an increased
M1 (tumour destructive) polarisation in macrophage in patients exhibiting high epithelial CTSS expression. In conclusion, our
observations suggest epithelial CTSS expression may be prognostic of improved outcome in TNBC. Improved outcome observed
with HER2+ at the gene expression level furthermore suggests CTSS may be prognostic of improved outcome in ER- cancers as a
whole. Lastly, from the context of these patients receiving adjuvant therapy and as a result of its association with BL1 subgroup CTSS
may be elevated in patients with defects in DNA damage repair pathways, indicating it may be predictive of tumour sensitivity to
DNA damaging agents.
1. Introduction
Breast cancer is a highly heterogeneous disease and may
be classified into different sub-types which affects treat-
ment approach and patient prognosis [1]. Classification of
breast cancer has been assigned via the presence/absence of
the estrogen receptor (ER) or HER2 amplification, which
allow use of targeted treatments such as tamoxifen and
trastuzumab, respectively. Tumour cells lacking these recep-
tors, in addition to the progesterone receptor (PR), are termed
“triple negative” (TNBC) and have the poorest outcome due
in part to the lack of targeted therapies available. TNBCs are
therefore typically treated with a cocktail of chemotherapies
such as FEC (5-FU, Epirubicin, and Cyclophosphamide).
Despite a high rate of response to chemotherapy, TNBC is
associatedwith high rates of relapse and death [2].This “triple
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negative paradox” is underpinned by a high level ofmolecular
heterogeneity [3]. In response to this, increased efforts have
been made to identify markers which may improve patient
outcome following diagnosis [4, 5], not only to allow better
treatment stratification but also to identify new therapeutic
targets.
The cysteine protease cathepsin S (CTSS) is one of a fam-
ily of 11 cysteine cathepsin proteases, and has been found to
be associated with a variety of pathologies, including cancer
[6, 7]. In contrast to othermembers of the cysteine cathepsins,
CTSS is normally constrained to macrophage and lymphoid
tissues. However, presence of CTSS has been observed in a
number of cancer types, including prostate [8, 9], gastric [10]
and hepatocellular [11] carcinomas. Furthermore, increased
CTSS expression has been shown to hold prognostic value in
grade IV astrocytomas [12], colorectal carcinomas [13], and
gastric cancer [14], where it is associatedwith a poor outcome.
Collectively, these observations have attracted interest in its
therapeutic potential in cancer [7].
The viability of targeting this protease in cancer has
been evaluated using pancreatic and colorectal carcinoma
gene depletion models [15–17], and treatment with a mono-
clonal antibody inhibitor FSN0503 [18] and a selective small
molecule inhibitor compound [19]. Inhibition/depletion of
CTSS produced reductions in tumour invasion, burden, pro-
liferation and vascularisation, as well as increased apoptosis.
Recently, Sevenich and colleagues examined the role of
CTSS in breast cancer progression, identifying a role for
CTSS in breast-to-brain metastases via cleavage of JAM-B, a
junctional adhesionmolecule involved in blood-brain barrier
transmigration [17]. However, the clinical utility of CTSS as
a biomarker in breast cancer has not been investigated to
date. In this study we therefore aimed to understand the
specific expression of CTSS, not only within epithelial and
stromal compartments in breast tumours, but also the known
molecular subgroups. This expression data was correlated
with clinical outcome to investigate the potential prognostic
and/or predictive role of CTSS.
2. Materials and Methods
2.1. Tissue Microarray Patient Sample Selection and Immuno-
histochemical Staining. All tissue samples were located from
the Belfast and the South Eastern Health and Social Care
Trust (BSHSCT) were obtained under the auspices of
the Northern Ireland Biobank (NIB) (www.nibiobank.org),
which has ethical approval (ref: 11/NI/0013) to collect,
store and distribute de-identified/anonymised samples to
researchers. The present study has ethical approval from
NIB approval (reference. NIB14-0125). Tissue microarray
study design, patient selection and construction of the
BR300 cohort has been described previously in Boyle et al.
[20]. This study was designed as outlined in Supplementary
Figure 1. Briefly, the patient cohort compiled 296 female
patients with de novo breast cancer and included matching
clinical, pathological and outcome parameters. All patients
within the cohort were diagnosed and received treatment
in Northern Ireland, with the vast majority of the tissue
resection samples obtained, processed and reported from
one of the two hospitals in the Belfast catchment area
between September 1997 and May 2009. All tissue data
presented here was obtained by surgical resection, com-
prising of total or partial mastectomies with axillary node
clearance. All patients present within the cohort subsequently
received anthracycline-based chemotherapy with or without
radiotherapy. Patients exhibiting positive hormone receptor
or HER2 status were administered hormone therapy or
trastuzumab. None of the patients were treated neoadju-
vantly. Patient exclusion criteria included male sex and past
history of any cancer type. Unique TNBC cases were collated
from two independent bespoke TNBC TMA cohorts avail-
able from the NIB and previously described in Humphries
et al. [21] and Orr et al. [22]. Immunohistochemical staining
of CTSS was carried out in the Northern Ireland Molecular
Pathology Laboratory (QUB). Sections were cut from the
TMA blocks to a diameter of 4 𝜇musing a rotary microtome,
dried at 37∘C overnight, and then used for immunohisto-
chemical staining with rabbit anti-human CTSS antibody
(1:250) (HPA002988, Atlas Antibodies, UK) using an auto-
mated immuno-stainer (Leica Bond-Max, UK). All sections
were visualised with DAB, counterstained with haematoxylin
and mounted in DPX. To avoid bias, scoring was carried out
by at least two independent assessors experienced in IHC
analysis in breast TMAs. Preliminary analysis revealed that
patients with a CTSS score of 0 and 1 behaved similarly
in terms of survival, as were patients with CTSS scores of
2 and 3. Patients were therefore stratified based on low
CTSS (score of 0 and 1) or high CTSS (score of 2 and 3)
expression, and the effect of expression on overall survival
observed.
2.2. Generation of Kaplan-Meier Curves for Analysis of TMA
and Publicly Available Gene Datasets. Matching clinical data
was obtained from the NIB upon completion of CTSS
scoring. The expression data was matched with the clinical
data according to the anonymous patient IDs usingMicrosoft
Excel. Evaluation of CTSS expression on survival was com-
pleted using non-censored data, and was subsequently anal-
ysed using GraphPad Prism.
Comparative analysis of gene expression versus
overall survival (2014; N=1117) and relapse free survival
(N=3971) was carried out using online repository KM
plotter (www.kmplot.com) [23]. Using the breast cancer
dataset, survival dependent on CTSS gene expression
was analysed based on intrinsic patient subtype, using a
collation of previously published and publicly available
Affymetrix microarray datasets, available through GEO,
European Bioinformatics Institute and TCGA. Gene
expression was evaluated using a median expression of
CTSS probes 202901 x at and 202902 s at. Patient overall
survival was split according to a median value cut-off point
into high/low expression and all the data right-censored
at 120 months (10 years). Data was obtained directly from
www.kmplot.com and the figures generated using GraphPad
Prism. Data was presented as percentage survival versus time
in months.
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Table 1: Clinicopathological information for BR300 tissue microarray categorised according to compartmental CTSS scores. CTSS scores of 0
and 1 behaved similarly in terms of survival, as were patients with CTSS scores of 2 and 3. Patients were therefore stratified based on low
CTSS (score of 0 and 1) or high CTSS (score of 2 and 3) expression. Differences between clinical information was evaluated based on high and
low CTSS scores in either the epithelial and stromal compartments. Statistical significance determined by Chi-Square test. Figure in brackets
indicates percentage of total. LVI=lymphovascular invasion. N=number of patients.
BR300 Cohort CTSS Epithelial CTSS Stromal
N (%) Low (%) High (%) p-value N (%) Low (%) High (%) p-value
Characteristic 267 (100) 221 (100) 46 (100) 262 (100) 79 (100) 183 (100)
Age N≤51 140 (52) 113 (51) 27 (59) 140 (53) 41 (52) 99 (54)
Median = 51 N>51 127 (48) 108 (49) 19 (41) 0.42 122 (47) 38 (48) 84 (46) 0.79
Grade 1 4 (1) 4 (2) 0 (0) 4 (2) 3 (4) 1 (1)
2 106 (40) 99 (45) 7 (15) 103 (39) 45 (57) 58 (32)
3 157 (59) 118 (53) 39 (85) 0.0004∗∗∗ 155 (59) 31 (39) 124 (68) < 0.0001∗∗∗
Tumour 1 54 (20) 45 (20) 9 (20) 54 (21) 14 (18) 40 (22)
2 171 (64) 146 (66) 25 (54) 166 (63) 52 (66) 114 (62)
3 36 (13) 24 (11) 12 (26) 36 (14) 11 (14) 25 (14)
4/4b 6 (2) 6 (3) 0 (0) 0.035∗ 6 (2) 2 (3) 4 (2) 0.9
Node 0 114 (43) 86 (39) 28 (61) 113 (43) 33 (42) 80 (44)
1 93 (35) 83 (38) 14 (30) 91 (35) 26 (33) 64 (35)
2 34 (13) 31 (14) 3 (7) 33 (13) 13 (16) 20 (11)
3 26 (10) 25 (11) 1 (2) 0.020∗ 26 (10) 7 (9) 19 (10) 0.66
LVI Yes 168 (63) 145 (66) 23 (50) 164 (63) 51 (65) 113 (62)
No 96 (36) 73 (33) 23 (50) 96 (37) 26 (33) 70 (38)
Unknown 3 (1) 3 (1) 0 (0) 0.076 3 (1) 2 (3) 1 (1) 0.3
Histology Ductal 210 (79) 172 (78) 38 (83) 207 (79) 49 (62) 158 (86)
Lobular 27 (10) 24 (11) 3 (7) 26 (10) 16 (20) 10 (5)
Mixed 24 (9) 21 (10) 3 (7) 23 (9) 12 (15) 11 (6)
Other 6 (2) 4 (2) 2 (4) 0.52 6 (2) 2 (3) 4 (2) < 0.0001∗∗∗
Radiotherapy Yes 220 (82) 182 (82) 38 (83) 215 (82) 70 (89) 145 (79)
No 47 (18) 39 (18) 8 (17) 1.00 47 (18) 9 (11) 38 (21) 0.080
Hormone Yes 157 (59) 147 (67) 10 (22) 157 (60) 65 (82) 88 (48)
Therapy No 110 (41) 74 (33) 36 (78) < 0.0001∗∗∗ 109 (42) 14 (18) 95 (52) < 0.0001∗∗∗
2.3. Analysis of CTSS and Macrophage Polarisation. BR300
CTSS epithelial scores were matched with CD68, CD14 and
CD163 IHC, previously stained and described by Buckley et
al. [24], and split according to no CTSS expression (score =
0) or CTSS expression (score = 1-3). Analysis of macrophage
polarisation by gene signatures was carried out as previously
described by Jezequel et al. and Denardo et al. [25, 26], using
gene expression collected and described in Buckley et al. [24].
2.4. Statistical Analysis. The TMA IHC clinicopathological
analysis and the macrophage IHC was analysed by Chi-
Square test. Differences in overall survival within the CTSS
BR300 and the TNBC bespoke IHC, as well as the publically
available gene expression (overall survival and relapse free
survival) were evaluated by Log-Rank test and hazard ratios
with 95% confidence limits reported. Statistical evaluation of
CTSS expression St. Gallen and Lehmann subtypes, as well
as the macrophage polarisation gene expression signatures
within the BR300 cohort, were analysed using one-way
ANOVA. Significance is defined as ∗p <0.05, ∗∗p <0.01, and
∗∗∗p <0.001.
3. Results
3.1. Patho-Physiological Characterisation of CTSS Expression
in the Patient Samples. To first investigate the role of CTSS
expression in breast cancer, we applied IHC of CTSS on
a tissue microarray (TMA) representing a cohort of 296
patients (hereafter referred to as BR300 cohort) [20]. Pre-
viously, several groups have indicated an importance for
either tumour infiltrating lymphocyte- (TIL-) derived [27]
or epithelial-derived CTSS expression [16] in tumour pro-
gression. Therefore, CTSS protein expression was evaluated
for epithelial and stromal compartments separately. Based
on initial assessment of staining patterns, expression was
categorised as either; 0: no expression, 1: low expression,
2: moderate expression and 3: high expression, in both
epithelial and stromal cells (Figure 1). When matched with
the clinical data, a significant association between increased
CTSS expression and tumour gradewas observed in epithelial
(p=0.0004) and stromal (p<0.0001) cells (Table 1). In addi-
tion, there was a significant association between high CTSS
expression, and increased tumour stage (p=0.035) in the
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Figure 1: Representative images of CTSS expression in patient samples. CTSS-specific expression is indicated by brown staining versus blue
nuclear counter staining. Samples represent either epithelial or stromal CTSS staining. Black arrows indicate areas of CTSS expression, which
was separated according to high (3), moderate (2), low (1), or no expression (0).
epithelial cells. We also observed decreased node (p=0.020)
as well as reduced lymphovascular invasion (LVI), which
approached significance, in patients with high epithelial
CTSS expression. Finally, increased expression of CTSS in
the stromal cells revealed a significant association with
ductal breast cancer (p<0.0001), though it is important to
note that the study is underpowered to robustly assess any
association with other histologies. No significant differences
were observed between histology and epithelial cell CTSS
expression, and no significant difference was observed in
the age of patients comparing high or low CTSS expression
in either epithelial or stromal cells. Interestingly, despite
no significant differences with respect to radiotherapy with
CTSS expression, a significantly larger number of patients
with high epithelial and stromal CTSS expression did not
receive hormone therapy, suggesting a negative association
between CTSS expression and ER status (p<0.0001) (Table 1).
3.2. Increased CTSS Expression in Epithelial Cells Associated
with Improved Outcome. Preliminary analysis revealed that
patients with a CTSS score of 0 and 1 behaved similarly
in terms of survival, as were patients with CTSS scores
of 2 and 3. Patients were therefore stratified based on
low CTSS (score of 0 and 1) or high CTSS (score of 2
and 3) expression, and the effect of expression on overall
survival analysed. The resulting Kaplan-Meier plots revealed
distinct patterns for epithelial and stromal cell CTSS expres-
sion with respect overall survival. Consistent with previ-
ous findings, high stromal CTSS expression was associ-
ated with poor outcome (HR=1.66 (CI=1.00-2.70) p=0.049)
(Figure 2(a)). Intriguingly, the opposite was observed with
respect to high epithelial CTSS expression, which was
highly significantly associated with an improved outcome
(HR=0.45 (CI=0.25-0.81) p=0.0082) (Figure 2(b)). This led
us to further investigate if the expression of epithelial-
derived CTSS was specific to certain sub-types of breast
cancer.
3.3. Increased Epithelial Cell CTSS Expression Is Associated
with Improved Outcome in Triple Negative Breast Cancer.
Following evaluation of CTSS protein expression and the
association with survival using the BR300 patient cohort, we
next wished to observe differential CTSS expression within
breast cancer subtypes. Patients were subdivided into their
respective subtypes according to St. Gallen classification [28].
While high CTSS was associated with good outcome, there
were very few cases, which prohibited further robust analysis
(Supplementary Figures 2(a)-2(e)).
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Figure 2: CTSS expression is differentially associated with patient outcome based on cell compartment. Kaplan-Meier curve stratified overall
survival (OS) based on high or low CTSS expression in (a) stromal and (b) epithelial compartment. Log-Rank p-value and hazard ratio (HR)
with 95% confidence intervals indicated. N=number of patients.
Interestingly, matching outcome data for the triple neg-
ative breast cancer patients (N=69) to the CTSS epithelial
expression revealed an association of high CTSS expression
with a significantly improved outcome (HR=0.37 (CI=0.14-
1.00) p=0.049) (Figure 3(a)(i)). Analysis of stromal CTSS
expression revealed a non-significant trend towards poor
outcome which may be due to the low number of patients
within the low CTSS expression arm (HR=1.68 (CI=0.36-
7.82) p=0.51) (Figure 3(a)(ii)).
To supplement this observation, scoring of CTSS in a
bespoke triple negative breast cancer cohort (N=84) was
carried out [21, 22]. Analysis of the stromal CTSS expression
revealed no significant difference to outcome, but reassur-
ingly, a trend complementing the outcome in the BR300
cohort was observed, with high CTSS epithelial expression
demonstrating improved outcome in triple negative breast
cancer patients, however, given the relatively small size of this
cohort, significance was not quite reached (p=0.073) (Fig-
ure 3(b)). To enhance statistical power, the two cohorts were
combined and as a result demonstrated a clear and significant
improvement for TNBC patients with epithelial derived
CTSS expression (HR=0.41 (CI=0.22-0.75) p=0.0036) (Fig-
ure 3(c)(i)) in contrast to stromal CTSS expression which
showed no significant difference to outcome (Figure 3(c)(ii)).
3.4. IncreasedCTSSGene ExpressionAssociatedwith Improved
Outcome in Triple Negative Breast Cancer. Given the results
from the TMA analysis, we investigated if CTSS gene
expression could also predict outcome. This allowed us to
interrogate the role of CTSS further using publicly available
gene expression datasets.We first validated the TMAfindings
using a gene expression dataset matched to the BR300 cohort
[29]. Consistent with the IHC analysis, we observed CTSS to
be expressed highest in TNBC (Figure 4(a)). Lehman subtype
analysis of the TNBC subgroup revealed CTSS expression
varied significantly across all subgroups with the highest
expression observed in the IM group and lowest expression
in the LAR and M groups (Figure 4(b) and Supplementary
Figure 3). Refinement of the Lehmann subtype study has
since shown that the molecular signatures defining the IM
and MSL groups were derived from infiltrating lymphocyte
and stromal cells [30]. Therefore the high CTSS expression
in the IM group is most likely associated with tumour
associated immune cells. Analysis of CTSS across the four
epithelial-derived subgroups displayed a significant variation
in expression as a whole with expression in the BL1 subtype
significantly higher than the LAR and M subtypes. Of note,
the BL1 subgroup is also associated with improved outcome
[30].
To supplement these observations made with our in-
house patient dataset, evaluation of the relationship of gene
expression and survival was carried out with publicly avail-
able datasets using KM Plotter [23]. The results indicated
no significant differences between high and low CTSS gene
expression on overall survival (OS) or relapse free survival
(RFS) of breast cancer patients as a whole (Supplementary
Table 1; Supplementary Figure 4). Further dissection of CTSS
expression with respect to individual subtypes revealed no
significant difference between high and low CTSS expression
on either OS or RFS in luminal A, nor luminal B (Supple-
mentary Table 1; Supplementary Figure 4). However, a strik-
ing significant correlation between CTSS and survival was
observed in HER2+ (OS HR=0.38 (CI=0.20-0.71) p=0.0031,
RFS HR=0.47 (0.32-0.70) p=0.0002) and TNBC patients (OS
HR=0.43 (CI=0.27-0.71) p=0.0009, and RFS HR=0.46 (0.36-
0.60) p<0.0001) (Figure 5) (Supplementary Table 1).
3.5. Expression of CTSS in TNBC Epithelial Cells Is Asso-
ciated with the Enhanced Presence of M1 Macrophages.
In order to understand some of the molecular pathol-
ogy underpinning the observed association between CTSS
and good outcome in TNBC patients, we interrogated the
tumour microenvironment for possible clues. Given the
association between CTSS expression with macrophages, we
6 Journal of Oncology
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Figure 3: Increased epithelial cell CTSS expression is associated with improved outcome in TNBC. Kaplan-Meier curves stratifying overall
survival (OS) of (a) the BR300 TNBC patients-alone, (b) the bespoke TNBC enriched cohort-alone, and (c) the combined BR300 and bespoke
TNBC cohorts, based on high or low CTSS expression in the (i) epithelial and (ii) stromal compartment. Log-Rank p-value and hazard ratio
(HR) with 95% confidence intervals indicated. N=number of patients.
decided to examine the expression of activated M1 (tumour
destructive) or alternatively activatedM2 (tumour protective)
macrophage polarisation markers in the context of CTSS
expression.
IHC scoring of CTSS in the TNBC epithelial cells
correlated significantly with an increased expression of
macrophagemarker CD68 (p=0.0011), indicative of increased
macrophage infiltration (Figure 6(a)). With this increased
presence of macrophages, there was a significant increase in
M1 marker CD14 (p=0.014) (Figure 6(b)), and no significant
change in the expression of M2 marker CD163 (Figure 6(c)).
Using two gene expression based algorithms [25, 26], previ-
ously utilised in our TNBC cohort [24], analysis revealed a
significant enhancement in M1-like phenotype with presence
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Figure 4:CTSS gene expression is highest in BR300 TNBC subtype and associated with DNA damage/cell cycle pathways.CTSS gene expression
was evaluated using an in house dataset containing 300 breast cancer patients. Analysis revealed (a) CTSS expression to be highest in TNBC.
(b) Lehman subgroups analysis of the TNBC patients revealed an association with the BL1 group which encompasses DNA damage and cell
cycle pathways. Significance for both panels was determined by one-way ANOVA. ∗p <0.05, ∗∗p <0.01, and ∗∗∗p <0.001.
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Figure 5: Analysis of publicly available gene expression datasets reveal improved outcome with high CTSS expression in HER2+ and TNBC
patients. Kaplan-Meier curves stratifying (a) HER2+ and (b) TNBC patients based on high or low CTSS expression and evaluating (i)
overall survival (OS) and (ii) relapse free survival (RFS). Log-Rank p-value and hazard ratio (HR) with 95% confidence intervals indicated.
N=number of patients.
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Figure 6: Epithelial cell CTSS expression in TNBC patients is associated with an M1 macrophage phenotype. Immunohistochemical epithelial
CTSS scores were matched with (a) macrophage marker CD68, (b) M1 polarisation marker CD14 and (c) M2 polarisation marker CD163.
Shading indicates proportion of IHC score for each marker. Statistical significance determined by Chi-Square analysis. Macrophage
polarisation was analysed using gene expression algorithms and correlated with CTSS IHC expression generating (d) M2/M1 and (e)
CD68/CD8 signature scores. Statistical significance determined by one-way ANOVA. N=number of patients. ∗p <0.05, ∗∗p <0.01, and
∗∗∗p <0.001.
of epithelial CTSS expression (p<0.001 and p<0.05) (Figures
6(d) and 6(e)).
Taken together, this suggests increased expression of
CTSS in the epithelial cells associates with increased
infiltration of M1 polarised macrophages thus resulting
a more immunocompetent microenvironment, and ratio-
nalises the improved survival observed with epithelial CTSS
expression in the TNBC sub-type.
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4. Discussion
In this study we have demonstrated a multifaceted role for
CTSS as a biomarker in TNBC. This investigation began
by observing differences in patient outcome based on CTSS
expression, with stromal-associated CTSS expression shown
to be associated with a poor outcome, whereas high CTSS
expression in epithelial cells is associated with an improved
outcome. Interestingly, the observation of epithelial CTSS
expression in TNBC patients revealed an association with
improved outcome, which remained consistent in gene
expression analysis. We furthermore observed increased M1
polarisation of macrophage in patients exhibiting high CTSS
expression in the epithelial cells. Taken together, we found
differential CTSS expression had compartmental and sub-
type effects on patient outcome, highlighting a potentially
novel role for this protease in TNBC.
Due to their potent and promiscuous proteolytic func-
tion, cysteine cathepsins have previously been implicated in a
number of pathological roles as a result of extracellularmatrix
remodelling including angiogenesis, invasion and metastases
[7]. As such, increased CTSS expression has been shown
be associated with poor clinical features in a number of
cancer types [8–11], as well as holding prognostic value with
expression associated with poor outcome in others [12, 13].
To the best of our knowledge, this is the first investigation
of CTSS expression in breast cancer using clinical samples
evaluating clinical outcome, and furthermore, accounting for
outcome based on epithelial or stromal CTSS expression.
We observed clinicopathological patterns with respect
CTSS expression and compartment type. When comparing
high versus low CTSS scores, we observed an increase in
the number of patients with grade 3 tumours with high
CTSS expression in both epithelial (53.39% low versus 84.78%
high) and stromal (39.24% low versus 67.76% in high) cells.
Furthermore, patients with high epithelial CTSS expression
also demonstrated decreased node scoring and LVI positivity,
indicators of improved outcome. In the epithelial cells, a
significant association with increased tumour stage was also
observed with high CTSS expression. These are consistent
with observations made elsewhere regarding CTSS expres-
sion in breast cancer [31]. Interestingly, high CTSS expression
in infiltrating cells was associated with poor outcome. This
is consistent with the increased aberrant expression of this
protease in other carcinomas where as a result of pro-
tumorigenic role of this protease in cancer, increased CTSS
has been associated with poor outcome reported as a result
of tumour associated macrophages (TAMs) [15]. In contrast
to this, CTSS expression in the epithelial cells displayed an
opposite phenotype. Upon further analysis of subtypes, and
within the context of this cohort, we found highCTSS expres-
sion to be associated with improved outcome with epithelial
CTSS expression in TNBC patients. Taken altogether, this
indicates a dual role for this protease in tumour development
based on compartmental and subtype expression.
Further in silico analysis confirmed these clinical outcome
findings, and also highlighted a potential association of
CTSS and outcome in the HER2+ subgroup, suggesting a
role for CTSS as a biomarker in ER- disease as a whole.
This complements the increased number of patients with
high epithelial CTSS who did not receive adjuvant hormone
therapy (78%), suggesting these tumours exhibit an ER- back-
ground. Interestingly, Gautam and colleagues also observed
an association between high epithelial CTSS expression and
ER- subtype [31]. From a clinical perspective, patients with
ER- breast cancers are significantly associated with poor
outcome compared to ER+ breast cancer patients, as they
lack the relevant targets for therapy [32–36]. Consequentially,
there is a real need to stratify these patients further, to
maximise improved outcome in patients. Based on our
observations, there may be value in further characterising
CTSS expression in a larger ER- patient comparative cohort,
as this protease may hold utility as a prognostic biomarker in
this setting.
An important feature of this study was the use of
patient samples who all received adjuvant treatment prior
to collection of tumour resections. Analysis of our in-house
TNBC gene expression dataset using the Lehmann subgroups
demonstrated an association of CTSS expression with the
BL1 group, characterised by defects in DNA damage repair
pathways. Interestingly, previous investigation using publicly
available gene datasets representing 300 TNBC patients who
received neo-adjuvant chemotherapeutic treatment, revealed
the BL1 subgroup to display the greatest pathological com-
plete response versus the BL2 and LAR patient subgroups
[30]. This suggests that expression of CTSS in epithelial cells
may be associated with tumours defective in DNA damage
repair, and therefore, indicates CTSS expression may be
predictive of sensitivity to DNA damaging chemotherapies.
Whilst this study has focused on IHC analysis of resected
tumours, others have demonstrated that CTSS levels can
be detected in patient serum for a variety of diseases [7].
Considering the suggested link between CTSS expression
from a prognostic and predictive perspective, it may be of
interest to further investigate in liquid biopsies.
The relevance of the tumour immune microenvironment
is becoming more important with the development of ther-
apeutic strategies to target this compartment [37]. Conse-
quentially, appreciation of underlying biological associations
between tumour and immune cells may help better guide
therapies in the future. Here we show a positive correlation
between TNBC epithelial derived CTSS expression and a
more favourable M1 microenvironment. The relationship
between CTSS and TAMs has been widely reported using
in vivo models [16, 17, 27, 38–40]. These studies have
highlighted the relevance of macrophages as a source of
CTSS at the tumour site. Furthermore, these studies have
associated an M2-marcophage phenotype (tumour protec-
tive), and have implicated CTSS in a modulating role via an
autophagy-mediated mechanism [40, 41]. Interestingly, the
epithelial CTSS expression in TNBC patients demonstrated
an enriched M1 polarisation phenotype, consistent with the
observed improved outcome. We believe this underlines a
more complex relationship between tumour epithelial and
stromal cell compartments than has been demonstrated
in pre-clinical models, and possibly between cancer types,
highlighting a need for further in-depth analysis in patient
samples.
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5. Conclusion
In conclusion, we have characterised the expression profile of
CTSS in breast cancer patient samples and have found that
both compartmental and subtype expression of this protease
can affect patient outcome. This study highlights a need for
further investigation into this protease within breast cancer,
to consolidate the potential predictive and prognostic utility
of CTSS expression in different subtypes. Furthermore, a
deeper appreciation of the biology underlying this disease
will help guide treatment regimens and possible application
of CTSS inhibitors in the future.
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